LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

LLY

1,111.22

-0.93%↓

JNJ

233.46

-0.82%↓

ABBV

221.03

-0.71%↓

UNH

399.31

-2.24%↓

NVS

150.89

0%↓

Search

Geron Corp

Gesloten

SectorGezondheidszorg

1.22 4.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.17

Max

1.27

Belangrijke statistieken

By Trading Economics

Inkomsten

25M

-3.6M

Verkoop

3.8M

52M

EPS

-0.005

Winstmarge

-7.026

Werknemers

258

EBITDA

27M

3.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+238.98% upside

Dividenden

By Acuity

Volgende Winsten

5 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-268M

738M

Vorige openingsprijs

-3.05

Vorige sluitingsprijs

1.22

Nieuwssentiment

By Acuity

49%

51%

164 / 342 Rangschikking in Healthcare

Geron Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
help-icon Live chat